# Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (Text with EEA relevance), Division 3.6.2.2.6: Some important factors which may be taken into consideration, when assessing the overall level of concern are:

Extent: E+W+S+N.I.

(a) tumour type and background incidence;
(b) multi-site responses;
(c) progression of lesions to malignancy;
(d) reduced tumour latency;
(e) whether responses are in single or both sexes;
(f) whether responses are in a single species or several species;
(g) structural similarity to a substance(s) for which there is good evidence of carcinogenicity;
(h) routes of exposure;
(i) comparison of absorption, distribution, metabolism and excretion between test animals and humans;
(j) the possibility of a confounding effect of excessive toxicity at test doses;
(k) mode of action and its relevance for humans, such as cytotoxicity with growth stimulation, mitogenesis, immunosuppression, mutagenicity.
Mutagenicity: it is recognised that genetic events are central in the overall process of cancer development. Therefore evidence of mutagenic activity in vivo may indicate that a substance has a potential for carcinogenic effects.

---
Source: https://www.legislation.gov.uk/eur/2008/1272/annex/I/division/3/division/3.6/division/3.6.2/division/3.6.2.2/division/3.6.2.2.6 (the official version)
Page: https://openlegislation.uk/eu-regulation-2008-1272/annex-I/division-3/division-3.6/division-3.6.2/division-3.6.2.2/division-3.6.2.2.6
Contains public sector information licensed under the Open Government Licence v3.0. Source: legislation.gov.uk, The National Archives.

